© 2023 FibroBiologics. All Rights Reserved
Board of Directors
Robert E. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fundraising, strategic planning, corporate governance, investor relations, and leadership.
Robert currently sits on four publicly-traded company boards with market capitalizations ranging from $30 million to $2.8 billion (Kura Oncology – Nasdaq: Kura, ASLAN Pharmaceuticals – Nasdaq: ASLN, Kintara Therapeutics – Nasdaq: KTRA, and Antibe Therapeutics – TSX: ATE) serving as Chairman of the Board of Kintara and as audit committee chair on the other boards. In his most recent operating role, Robert was CFO of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. Robert’s career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he was a member of the founding management team and rose to become CFO, holding that position for ten years. While at Arena, he was involved in its IPO and financings, raising more than $1.5 billion. Robert was the financial lead in two Arena acquisitions, including a Swiss manufacturing facility that he became managing director of the facility upon the closing of the transaction. Robert was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Charity work is important to Robert. As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Robert has served on its board of directors for 20 years. Robert received his BBA in accounting from St. Bonaventure University and is a licensed CPA (Inactive) in the State of California.